{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:42:54Z","timestamp":1792662174746,"version":"4.5.0"},"reference-count":10,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["RAIAD"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Angiotensin II receptor blockers (ARBs) are a group of drugs widely\nused in the treatment of high blood pressure, cardiovascular and renal diseases, and diabetes.\nARBs have a low incidence of adverse effects and are usually well tolerated. A limited number\nof cutaneous reactions to ARBs have been reported. To date, there are no published reports of\nimmediate drug hypersensitivity reactions to any ARB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation:<\/jats:title>\n                    <jats:p>We present a 50-year-old woman with a personal history of arterial hypertension\nand dyslipidemia. She started treatment with valsartan at 160 mg per day. A year later,\nshe began to experience daily episodes of papular and pruritic skin lesions. She was treated with\noral and topical corticosteroids and antihistamines, but the exanthema persisted and progressively\nworsened. Valsartan was finally discontinued, and she has not experienced any new flares\nsince then. A punch skin biopsy was performed, and histological results were consistent with an\neczematous pattern of toxicodermia. Blood analysis, including serum immunoglobulins, complement\nproteins, and peripheral eosinophils, showed normal values. Patch tests and a skin prick\ntest with valsartan were negative. A controlled oral challenge with valsartan was performed,\nyielding a positive result. Thirty minutes after the second dose of the drug (cumulative dose of\n160 mg), the patient developed an urticarial rash, which resolved within the following two\nhours. An alternative ARB was selected for challenge, and a controlled oral challenge test with\nlosartan was successfully completed without adverse reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This is the first immediate reaction to an ARB, specifically valsartan, reported in\nthe literature. Only a few cases of cutaneous exanthemas suggestive of non-immediate drug hypersensitivity\nreactions have been reported previously. We present a patient with an initial suspicion\nof a delayed drug hypersensitivity reaction to valsartan, based on a biopsy consistent with\nan eczematous pattern of toxicodermia. After re-exposure to the drug four months later, the patient\nexperienced an immediate urticarial reaction, suggestive of an IgE-mediated drug allergy.\nCross-reactivity between ARBs is uncertain, but losartan, despite belonging to the same group\nof biphenyltetrazoles as valsartan, was demonstrated to be a safe ARB option for this patient.\nWe also hypothesize that the concept of the \u201cconverter phenotype,\u201d currently described in patients\ntreated with chemotherapy drugs and monoclonal antibodies, may be applicable to other\ndrugs as well.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0127722708420100260210104129","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T09:58:29Z","timestamp":1774864709000},"page":"466-469","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["An Unexpected Cutaneous Reaction to Valsartan in a Patient with Suspected Eczematous Pattern Toxicodermia: A Case Report"],"prefix":"10.2174","volume":"20","author":[{"given":"Luc\u00eda","family":"Gonzalez-Bravo","sequence":"first","affiliation":[{"name":"Allergy Unit, Hospital Universitario Pr\u00edncipe de Asturias, Departamento de Medicina y Especialidades M\u00e9dicas, Universidadde Alcal\u00e1, Alcal\u00e1 de Henares, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Barbarroja-Escudero","sequence":"additional","affiliation":[{"name":"Allergy Unit, Hospital Universitario Pr\u00edncipe de Asturias, Departamento de Medicina y Especialidades M\u00e9dicas, Universidadde Alcal\u00e1, Alcal\u00e1 de Henares, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Laiseca","family":"Anton","sequence":"additional","affiliation":[{"name":"Allergy Unit, Hospital Universitario Pr\u00edncipe de Asturias, Departamento de Medicina y Especialidades M\u00e9dicas, Universidadde Alcal\u00e1, Alcal\u00e1 de Henares, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melchor","family":"Alvarez-Mon","sequence":"additional","affiliation":[{"name":"Allergy Unit, Hospital Universitario Pr\u00edncipe de Asturias, Departamento de Medicina y Especialidades M\u00e9dicas, Universidadde Alcal\u00e1, Alcal\u00e1 de Henares, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefa","family":"Monjo-Paz","sequence":"additional","affiliation":[{"name":"Allergy Unit, Hospital Universitario Pr\u00edncipe de Asturias, Departamento de Medicina y Especialidades M\u00e9dicas, Universidadde Alcal\u00e1, Alcal\u00e1 de Henares, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Matas-Dominguez","sequence":"additional","affiliation":[{"name":"Allergy Unit, Hospital Universitario Pr\u00edncipe de Asturias, Departamento de Medicina y Especialidades M\u00e9dicas, Universidadde Alcal\u00e1, Alcal\u00e1 de Henares, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MarIa-Jos E","family":"Sanchez-Gonzalez","sequence":"additional","affiliation":[{"name":"Allergy Unit, Hospital Universitario Pr\u00edncipe de Asturias, Departamento de Medicina y Especialidades M\u00e9dicas, Universidadde Alcal\u00e1, Alcal\u00e1 de Henares, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1152\/physiol.00036.2020","volume":"36","author":"Saavedra J.M.","year":"2021","unstructured":"Saavedra J.M.; Angiotensin receptor blockers are not just for hypertension anymore. Physiology (Bethesda)  2021,36(3),160-73","journal-title":"Physiology (Bethesda)"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1157\/13092029","volume":"6","author":"Tamargo J.","year":"2006","unstructured":"Tamargo J.; Caballero R.; G\u00f3mez R.; N\u00fa\u00f1ez L.; Vaquero M.; Delp\u00f3n E.; Pharmacological characteristics of ARBs. Are they all the same? Rev Esp Cardiol  (Suppl. C)2006,6,10-24","journal-title":"Rev Esp Cardiol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.23736\/S0392-0488.19.06360-0","volume":"155","author":"Baccino D.","year":"2020","unstructured":"Baccino D.; Merlo G.; Cozzani E.; Cutaneous effects of antihypertensive drugs. G Ital Dermatol Venereol  2020,155(2),202-11","journal-title":"G Ital Dermatol Venereol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1080\/09546634.2022.2089332","volume":"33","author":"Lo Y.","year":"2022","unstructured":"Lo Y.; Tsai T.F.; Angiotensin II receptor blockers in dermatology: a narrative review. J Dermatolog Treat  2022,33(7),2894-8","journal-title":"J Dermatolog Treat"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3109\/15569527.2011.647179","volume":"31","author":"Ozturk G.","year":"2012","unstructured":"Ozturk G.; Turk B.G.; Senturk B.; Turkmen M.; Kandiloglu G.; Exanthematous drug eruption due to valsartan. Cutan Ocul Toxicol  2012,31(4),335-7","journal-title":"Cutan Ocul Toxicol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1111\/j.1365-2230.2009.03283.x","volume":"34","author":"Gencoglan G.","year":"2009","unstructured":"Gencoglan G.; Ceylan C.; Kazandi A.C.; Linear lichenoid drug eruption induced by valsartan. Clin Exp Dermatol  2009,34(7),e334-5","journal-title":"Clin Exp Dermatol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2340\/00015555-0695","volume":"90","author":"Sawada Y.","year":"2010","unstructured":"Sawada Y.; Yoshiki R.; Kawakami C.; Valsartan-induced drug eruption followed by CD30+ pseudolymphomatous eruption. Acta Derm Venereol  2010,90(5),521-2","journal-title":"Acta Derm Venereol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S0025-7753(00)71374-1","volume":"114","author":"Serna Higuera C.","year":"2000","unstructured":"Serna Higuera C.; Angioedema y reacci\u00f3n urticariforme inducidos por valsart\u00e1n. Med Cl\u00edn (Barc)  2000,114(15),599","journal-title":"Med Cl\u00edn (Barc)"},{"key":"ref=9","first-page":"811","volume":"73","author":"Jimenez-Rodriguez T.W.","year":"2018","unstructured":"Jimenez-Rodriguez T.W.; Alvarez Labella M.; Garcia-Neuer M.; Lynch D.M.M.; Castells M.; Abstract 1769 delayed hypersensitivity reactions to taxane can progress to Type I reactions: Management with desensitization. Allergy  2018,73,811","journal-title":"Allergy"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"785259","DOI":"10.3389\/falgy.2021.785259","volume":"2","author":"Jimenez-Rodriguez T.W.","year":"2022","unstructured":"Jimenez-Rodriguez T.W.; Manuel Marco de la Calle F.; Lozano-Cubo I.; Converter phenotype: A new profile that is not exclusive to taxanes. Front Allergy  2022,2,785259","journal-title":"Front Allergy"}],"container-title":["Recent Advances in Inflammation &amp; Allergy Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127722708420100260210104129","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/251525\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127722708420100260210104129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:25:56Z","timestamp":1792661156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/251525\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0127722708420100260210104129","relation":{},"ISSN":["2772-2708"],"issn-type":[{"value":"2772-2708","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-07-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}